Yostena Mekhail, MD, PhD
@MekhailYN
Followers
107
Following
183
Media
2
Statuses
133
I am an Oncologist with interest in drug development and biomarker-driven therapies.
Joined March 2024
RT @JIPOEditors: #JIPO received its 1st official #impactfactor = 3.2! .Immunology/Oncology Rank: Q2/Q3. We thank everyone who contributed t….
0
9
0
RT @gerlach_d: Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator | Cancer Discov….
0
9
0
RT @JIPOEditors: Sheshadri et al. comments on recent case report "Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with….
0
2
0
RT @DFCI_BreastOnc: Excellent #ASCO25 infographic highlighting the results of the DESTINY-Breast09 study:.👉Participants in the #TDXd + #Per….
0
13
0
RT @PTarantinoMD: Very promising data with KAT6 inhibition + fulvestrant presented by Pat LoRusso. Among 43 pts with HR+/HER2- MBC, all wit….
0
31
0
RT @PTarantinoMD: One week to #ASCO25. Which will be an unprecedented ASCO for breast oncologists. Treatment algorithms will change for ALL….
0
134
0
RT @AACR: The KRAS G12D inhibitor zoldonrasib elicited responses in patients with KRAS G12D-mutated non-small cell #LungCancer in a phase I….
0
17
0
RT @FaltasLab: 🎤 Aiming to cure cancer? Start systemic therapy early!.I am excited to present the interim results of our investigator-initi….
0
17
0
RT @Annals_Oncology: 🆕article in press: Copenhagen Prospective Personalized Oncology (CoPPO) – Impact of comprehensive genomic profiling i….
0
14
0
RT @OncoAlert: Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in….
0
8
0
RT @isliquidbiopsy: 🚨 cfRNA is Here — and It’s a Game Changer! 🧬🩸.@max_diehn et al., @Nature 2025. 🔗 DOI: 10.1038/s41586-025-08834-1. 👏 F….
0
16
0
RT @JIPOEditors: Falchook et al. summarize past and current CDK2 inhibitors in clinical trials in this #JIPO review .
0
2
0
RT @FaltasLab: 🧩 ctDNA is a key piece of the puzzle in building an integrated precision oncology ecosystem at @WeillCornell. Excited to sha….
0
31
0
RT @isliquidbiopsy: 🚨 ESMO’s New Global Guidelines for Molecular Tumor Boards (MTBs) 🧬💻. Published in Annals of Oncology, this comprehensiv….
0
12
0
RT @FaltasLab: 1/ Excited to share our new paper in @npjDigitalMed. We worked with @feiwang03 to develop a cutting-edge AI model 🖥️ that pr….
0
28
0
RT @matteolambe: Just published in @JCO_ASCO the updated @ASCO guidelines on fertility preservation in people with #cancer: a must read for….
0
199
0
RT @Dr_ElvinaA: @FDA approves pembrolizumab + trastuzumab + chemo for 1L treatment of metastatic HER2+ gastric cancer (PD-L1 CPS ≥1). ✅ P….
fda.gov
Hematology / Oncology News Burst
0
14
0
RT @JIPOEditors: Falchook et al. #review a new #clinicaltrial "Cyclin Dependent Kinase 2 (CDK2) Inhibitors in Oncology Clinical Trials" htt….
0
1
0
RT @PTarantinoMD: The 19th St. Gallen Conference took place this week in Vienna. Nearly 80 expert panelists voted on key debated topics in….
0
169
0